JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
See More: http://goo.gl/tW6DQL
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2.3 Upcoming Related Reports 25<br />
3 Disease Overview 26<br />
3.1 Etiology <strong>and</strong> Pathophysiology 26<br />
3.1.1 Etiology 26<br />
3.1.2 Pathophysiology 29<br />
3.2 Symp<strong>to</strong>ms 30<br />
3.2.1 Quality of Life 31<br />
4 Epidemiology 32<br />
4.1 Disease Background 32<br />
4.2 Risk Fac<strong>to</strong>rs <strong>and</strong> Comorbidities 33<br />
4.2.1 Being Caucasian <strong>and</strong> Jewish can increase the risk of UC by almost 37 times<br />
34<br />
4.2.2 A family his<strong>to</strong>ry of UC in first-degree relatives can increase the risk of the<br />
disease by almost three-fold 34<br />
4.2.3 Current smokers have a lower risk of developing UC than former smokers or<br />
never smokers 35<br />
4.3 <strong>Global</strong> Trends 36<br />
4.3.1 US 37<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language